Ocrevus Zunovo with Halozyme's Enhanze drug delivery technology is used for the treatment of relapsing multiple sclerosis and ...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Sept. /PRNewswire/ -- USA News Group – Cancer rates are rising glob ...

Fintel reports that on September 19, 2024, JP Morgan downgraded their outlook for Halozyme Therapeutics (NasdaqGS:HALO) from ...

Halozyme Therapeutics (HALO) stock drops after J.P. Morgan downgrade, but analyst raises price target on Enhanze drug ...

Halozyme Therapeutics, Inc. (HALO) stock saw a decline, ending the day at $61.93 which represents a decrease of $-0.98 or -1.56% from the prior close of $62.91. The stock opened at $62.91 and touched ...

Kaskela Law LLC announces that it is investigating Halozyme Therapeutics, Inc. ("Halozyme") on behalf of the company's shareholders. The investigation seeks to determine whether Halozyme and/or the ...

Roche has secured approval from the US Food and Drug Administration (FDA) for Ocrevus Zunovo (ocrelizumab and ...

Halozyme Therapeutics, Inc. (HALO) stock saw a modest uptick, ending the day at $62.3 which represents a slight increase of $1.76 or 2.91% from the prior close of $60.54. The stock opened at $61.02 ...

Halozyme announces US FDA approval of Roche's Tecentriq Hybreza with Enhanze for multiple types of cancer: San Diego Saturday, September 14, 2024, 12:00 Hrs [IST] Halozyme Therape ...

Trialbee, the global leader in technology-driven patient recruitment for clinical trials, is thrilled to announce the appointment of John Murray to its Advisory Board. With a distinguished career ...

It’s better late than never for an FDA approval for the first subcutaneous PD-L1 inhibitor, which was doled out to Roche’s ...